EP3846816A4 - Neuroprotective agents for treatment of neurodegenerative diseases - Google Patents

Neuroprotective agents for treatment of neurodegenerative diseases Download PDF

Info

Publication number
EP3846816A4
EP3846816A4 EP19858466.6A EP19858466A EP3846816A4 EP 3846816 A4 EP3846816 A4 EP 3846816A4 EP 19858466 A EP19858466 A EP 19858466A EP 3846816 A4 EP3846816 A4 EP 3846816A4
Authority
EP
European Patent Office
Prior art keywords
treatment
neurodegenerative diseases
neuroprotective agents
neuroprotective
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19858466.6A
Other languages
German (de)
French (fr)
Other versions
EP3846816A1 (en
Inventor
Aloke K. Dutta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/124,974 external-priority patent/US10874669B2/en
Priority claimed from US16/154,301 external-priority patent/US20190038622A1/en
Application filed by Wayne State University filed Critical Wayne State University
Publication of EP3846816A1 publication Critical patent/EP3846816A1/en
Publication of EP3846816A4 publication Critical patent/EP3846816A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP19858466.6A 2018-09-07 2019-09-06 Neuroprotective agents for treatment of neurodegenerative diseases Pending EP3846816A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/124,974 US10874669B2 (en) 2012-11-29 2018-09-07 Neuroprotective agents for treatment of neurodegenerative diseases
US16/154,301 US20190038622A1 (en) 2012-11-29 2018-10-08 Neuroprotective agents for treatment of neurodegenerative diseases
PCT/US2019/049927 WO2020051435A1 (en) 2018-09-07 2019-09-06 Neuroprotective agents for treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EP3846816A1 EP3846816A1 (en) 2021-07-14
EP3846816A4 true EP3846816A4 (en) 2022-08-17

Family

ID=69723262

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19858466.6A Pending EP3846816A4 (en) 2018-09-07 2019-09-06 Neuroprotective agents for treatment of neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP3846816A4 (en)
CA (1) CA3111561A1 (en)
WO (1) WO2020051435A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724758A (en) * 2021-08-24 2023-03-03 杭州中美华东制药有限公司 Camptothecin derivative intermediate, synthetic method thereof and method for synthesizing camptothecin derivative by using intermediate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085600A1 (en) * 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP3846816A1 (en) 2021-07-14
WO2020051435A1 (en) 2020-03-12
CA3111561A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
IL288523A (en) Compounds for treatment of pd-l1 diseases
EP3621973A4 (en) Compounds for the prevention and treatment of diseases and the use thereof
EP3448851B8 (en) Di-substituted pyrazole compounds for the treatment of diseases
EP4045036A4 (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
EP3773629A4 (en) Car-treg-based therapies for treating neurodegenerative diseases
EP3600286A4 (en) Compounds and methods for the treatment of parasitic diseases
EP4045037A4 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
EP3573617A4 (en) Therapeutic agent for liver diseases
EP3856243A4 (en) Methods of treating neurodegenerative diseases
EP3805216A4 (en) Compounds for treatment or prevention of liver diseases
EP3947390A4 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
EP3634394A4 (en) Compositions for treating neurodegenerative diseases
GB201714307D0 (en) Treatment of neurodegenerative diseases
EP3619204A4 (en) Compounds for the treatment of respiratory diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
IL273929A (en) Therapeutic agents for neurodegenerative diseases
EP3862012A4 (en) Therapeutic agent for neurodegenerative disease
EP3897602A4 (en) Pharmaceutical combinations for the treatment of cancer
EP3283457A4 (en) Compounds and methods for the treatment of neurodegenerative diseases
EP3761982A4 (en) Treatment of demyelinating diseases
EP3706867A4 (en) Therapeutic combination for treatment of cerebellar ataxia
EP3846816A4 (en) Neuroprotective agents for treatment of neurodegenerative diseases
EP3672583A4 (en) Compositions and methods for treating neurodegenerative diseases
EP3534954A4 (en) Compounds for treatment of neurodegenerative diseases
EP3755334A4 (en) Treatment of liver diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210308

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/16 20060101ALI20220408BHEP

Ipc: A61P 25/28 20060101ALI20220408BHEP

Ipc: A61K 31/4184 20060101ALI20220408BHEP

Ipc: A61K 31/137 20060101ALI20220408BHEP

Ipc: A61K 31/428 20060101ALI20220408BHEP

Ipc: A61K 31/496 20060101ALI20220408BHEP

Ipc: A61K 31/495 20060101AFI20220408BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031497000

Ipc: A61K0031495000

A4 Supplementary search report drawn up and despatched

Effective date: 20220715

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/16 20060101ALI20220711BHEP

Ipc: A61P 25/28 20060101ALI20220711BHEP

Ipc: A61K 31/4184 20060101ALI20220711BHEP

Ipc: A61K 31/137 20060101ALI20220711BHEP

Ipc: A61K 31/428 20060101ALI20220711BHEP

Ipc: A61K 31/496 20060101ALI20220711BHEP

Ipc: A61K 31/495 20060101AFI20220711BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240514